Gilbert syndrome, a benign unconjugated hyperbilirubinemia without structural liver disease or overt hemolysis, is characterized by episodes of mild intermittent jaundice (1) (2) (3) . Gilbert syndrome is the most common inherited variant of hepatic bilirubin metabolism, occurring in 2-12% of the population, and it is often detected in adulthood during routine blood tests. The most consistent feature in Gilbert syndrome is a deficiency in bilirubin glucuronidation, but the metabolism of drugs may also be affected (3 ) .
Recently, the molecular basis of Gilbert syndrome was elucidated and found to result from molecular lesions in one of the isoforms of the UDP-glucuronosyl transferase (UGT-1A) gene. UGT-1A is encoded by the UDG gene complex, which is composed of multiple unique forms of exon 1, each one specific for a single isoenzymes, and four common exons (from two to five) (4 ) . UGT-1A is responsible for bilirubin glucuronidation; the other isoenzymes of the complex are involved in the metabolism of a number of aromatic compounds (5 ) .
The most common genetic alteration of UGT-1A is a TA insertion in the repetitive TATA-box of the gene promoter, which normally consists of six repeats. The TA (7) allele causes reduced expression of the gene, and homozygosity for this allele is typically associated with a mild form of Gilbert syndrome (6 ) .
The aim of this study was to analyze the relationship between the TA variant reported by Bosma et al. (4 ) and the serum concentration of bilirubin in 98 unrelated subjects from all regions of Italy.
We collected whole blood (3 mL) into potassium EDTA and heparin-containing tubes from 98 subjects: 45 females, ages 2-23 years, and 53 males, ages 2-30 years, unselected for serum bilirubin concentrations and with no abnormal biochemical values. In our laboratory, the upper limit of the serum total bilirubin (STB) reference interval is 17.1 mol/L. All of the subjects were nonsmokers who had fasted overnight and who had not taken any medication or alcohol in the 5 days before blood collection. We measured alanine aminotransferase, albumin, alkaline phosphatase, amylase, ␥-glutamyltransferase, and total bilirubin on a Hitachi 917 (Roche Diagnostics). To measure total bilirubin, we used the Bilirubin DPD Method, with an interassay CV of 8%. DNA was prepared using the Istagene Matrix extraction kit (Bio-Rad Laboratories).
Primers (5Ј GTCACGTGACACAGTCAAAC 3Ј and 5Ј TTTGCTCCTGCCAGAGGTT 3Ј) from Bosma et al. (4 ) were used to amplify a fragment of 98 -100 bp. Amplifications (25 L) were performed using the four deoxynucleotide triphosphates (0.1 mmol/L each), 0.25 mol/L each primer, 1.5 mmol/L MgCl 2 , 0.5 U of Taq Polymerase, and 1ϫ buffer from PE Applied Biosystem. The PCR conditions (Perkin-Elmer 2400 Thermal cycler) were as follows: 95°C for 5 min, followed by 30 cycles of 95°C for 30 s, 58°C for 40 s, and 72°C for 40 s.
Amplification was confirmed before direct sequencing by an automated capillary electrophoresis DNA sequencer (ABI PRISM 310; PE Applied Biosystem) and the Big Dye Terminator Kit (PE Applied Biosystem).
Mean serum bilirubin values were compared by ANOVA or a two-tailed nonparametric Wilcoxon test. A t-test was used to evaluate whether the difference in age between males and females was significant; 2 tests were used to assess whether the distribution of the 6/6, 6/7, and 7/7 genotypes between males and females was significant: P Ͻ0.05 was considered significant.
Among 98 healthy subjects, 16 were homozygous for A(TA)7TAA (16.3%), 43 were homozygous for A(TA6)TAA (43.9%), and 39 were heterozygous (39.8%). The calculated allele frequency for the longer TATAA element was 0.36.
The mean (SD) serum bilirubin concentration was 7.7 (2.9) mol/L in the subjects who were homozygous for A(TA)6TAA, 9.6 (3.9) mol/L in the subjects who were heterozygous (P Ͻ0.05), and 25.1 (15.9) mol/L (P Ͻ0.001) in the subjects homozygous for A(TA)7TAA (Table 1.).
There were no significant differences in age or genotype distribution between males and females. There also were no significant differences in STB concentrations between males and females when divided by genotype. The genotype frequencies and mean (SD) STB concentrations for males and females are compared in Table 1 .
The clinical suspicion of Gilbert syndrome often is based on intermittent jaundice and/or a consistent mildly increased nonfasting total bilirubin as the sole abnormal liver-function test (1, 2 ) .
The recent demonstration of a UGT-1A alteration in There is a need to establish health-associated reference values for quantities measured in the clinical chemistry laboratory, but the idea of health is problematic (8, 9 ) .
The high frequency of variant allele TA7 and its significant influence on STB suggests the desirability of exclusion of these subjects from the selection of reference individuals for bilirubin determination.
In our 43 subjects homozygous for the wild-type TA6 allele, the upper limit of the conventional 95% reference interval was 14.4 mol/L, compared with the upper limit of 17.1 mol/L currently used in our laboratory (10 ) .
Serum iron concentrations Ͼ42.3 mol/L (Ͼ250 g%) seen in childhood iron poisoning may be high enough to exceed the total number of transferrin binding sites in serum and are associated with marked toxicity (1, 2 ) .
Concerns over iron toxicity related to this "oversaturation" of transferrin have recently been applied to circumstances in which iron is given intravenously as either iron dextran (used in the US) or iron gluconate to patients on hemodialysis receiving erythropoietin therapy (3, 4 ) . A recent study describing oversaturation of transferrin, as calculated by the measurement of high serum iron concentrations shortly after intravenous iron gluconate treatment, suggested that with this product, transferrin saturation is commonly Ͼ100% (serum iron/total iron binding capacity for transferrin binding sites ϫ 100 ϭ % saturation) (3 ). When transferrin is fully saturated, serum may contain "free" iron or iron loosely bound to other plasma proteins, a situation that can cause acute toxicity, including tissue damage, cardiac arrhythmias, and/or hypotension (1, 2 ) . It has been suggested that this oversaturation soon after intravenous iron infusion in hemodialysis patients may account for these types of complications (3 ). However, parenteral iron is a necessary treatment in this patient population, and similar complications, particularly hypotension, are common during hemodialysis sessions even when iron is not given (4 ) .
Because iron bound to iron dextran or iron gluconate does not cause acute iron toxicity (5 ), we hypothesized that serum assays for iron measure the iron present in these complexes after intravenous infusion, which produces misleadingly high results for the oversaturation of transferrin.
Pharmacokinetic studies have indicated that after infusion, serum concentrations of dextran-bound iron are distributed almost entirely in the plasma, with removal limited to the reticulo-endothelial system at a constant rate (3, (5) (6) (7) . Previous studies in iron-deficient patients have suggested that dextran has a variable, but in some patients a relatively long, half-life of Ͼ20 h in the circulation (5-7 ) . In a recent study, a mean half-life of 58.9 h was measured in patients with iron deficiency and chronic disease, including renal failure patients on hemodialysis receiving Dexferrum (8 ) . Various modifications of methodology have given conflicting results as to whether iron as iron dextran is measured as "serum iron" (5, 7 ) . When one methodology was used (5 ), Ͻ3% of the iron present as iron dextran was measured (5 ), and it was suggested this small percentage was bioavailable iron already dissociated from the iron dextran complex (5 ). However, another study, in which a different methodology was used, indicated that serum iron measurements up to 2 weeks after iron dextran injection could overestimate the amount of serum iron bound to transferrin (bioavailable iron); this overestimation was attributed to dissociation of the iron from iron dextran in the assay used (6, 7 ) .
The potential for incorrect diagnosis of oversaturation of transferrin may increase with the introduction of an iron gluconate preparation that recently was approved for use in the US (9 ) . To address this oversaturation question and to assess routine clinical monitoring guidelines (4 ), we measured serum iron in vitro in the presence of added iron gluconate as well as iron dextran.
